Adam Kittai, MD, of the Icahn School of Medicine at Mount Sinai, joins Blood Cancers Today at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas, to discuss Richter transformation in chronic lymphocytic leukemia (CLL).
Dr. Kittai described three trials evaluating novel therapies for Richter transformation:
- Pirtobrutinib
- Zanabrutinib plus tislelizumab
- Chimeric antigen receptor T-cell (CAR-T) therapy
“There’s encouraging data out there using our new medications for Richter transformation, but we still have a lot of work to do to figure out how best to treat these patients,” Dr. Kittai said.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.